Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Egypt / NCT07555821
Starting soon Phase 2/3

Improving Postoperative Analgesia After Functional Endoscopic Surgery

NCT07555821 · tracked via the Priya Life Science Egypt tracker
Sponsor
South Egypt Cancer Institute
Phase
Phase 2/3
Started
2026-04-15
Last updated
2026-04-29

Condition(s) studied

Pain Management After Functional Endoscopic Sinuscopy

Investigational drug(s) / intervention(s)

Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine: Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine

Study summary

Improving postoperative analgesia after functional endoscopic surgery: Sphenopalatine ganglion block versus soaked nasal packing using bupivacaine and dexmedetomidine

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 18 - 60 years 2. ASA physical status I -II 3. Patients scheduled for elective FESS Exclusion Criteria: 1. Allergy to drugs used 2. Coagulopathy or anticoagulant therapy 3. Severe cardiovascular, renal and hepatic disease 4. Chronic opioid use Pregnancy

Primary outcome measure(s)

  • effectiveness of SPGB with bupivacaine and dexmedetomidine for postoperative analgesia — 6 months
    Numeric rating scale for pain will be assessed and recorded within the first 24 hours where 1 means the worst pain and 10 means no pain. Total rescue analgesia in 24 H when Numeric rating scale ≥ 4 was recorded and the first time when it was given will be recorded.

Trial sites (1)

FacilityCityRegionStatus
Assiut university hospital Asyut Egypt

More South Egypt Cancer Institute trials in Egypt

Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07555821 on ClinicalTrials.gov ↗ ← All trials in Egypt